Safety issues in semen banks during the COVID-19 pandemic: data from a European survey

Abstract

Purpose

We performed a survey among European semen banks enquiring safety protocols during the COVID-19 pandemic. We report the experience from a center searching SARS-CoV-2 mRNA in semen of patients undergoing cryopreservation from May 2020 to January 2021.

Methods

A questionnaire was submitted to accredited semen banks of the European Academy of Andrology (EAA) and the Italian Society of Andrology and Sexual Medicine (SIAMS). A total of 22 centers answered to the survey. SARS-CoV-2 mRNA in semen was evaluated by RT-PCR in 111 subjects banking in the Semen Bank of Careggi University Hospital (Florence, Italy).

Results

No particularly drastic safety measures were adopted by the majority of the centers to prevent the risk of contamination or transmission of the virus. The most common strategy (77.3%) was the administration of an anamnestic questionnaire. About half of the centers request a negative nasopharyngeal swab (NPS) before cryopreservation. Few centers use a quarantine tank, in case of late response of NPS, and only 4 store in a dedicated tank in case of infection. SARS-CoV-2 mRNA was not found in 111 semen samples cryopreserved in the Florentine bank.

Conclusions

European semen banks use different measures to handle semen samples for cryopreservation during COVID-19 pandemic. The request of NPS is advised to better manage couples undergoing ART and to protect the personnel operating in the bank/ART center. Finally, due to the areas of uncertainties of an almost unknown virus, it is absolutely recommended the use of safe devices for sample handling and storage.

Introduction

From December 2019, a form of pneumonia caused by a virus belonging to the Coronavirus family developed in China and it soon spread all over the world [1]. The World Health Organization (WHO) named such virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona-Virus-2) and the relative infection COVID-19 (Corona Virus Disease 19) and, in March 2020, declared it pandemic. Since its onset, the disease has affected millions of people with a variable course, from no or few symptoms to death.

Although the main route of transmission is respiratory droplets, there is evidence of the presence of SARS-CoV-2 RNA in various biological matrices such as stool, blood and urine samples [2]. This suggests that other routes of infection are theoretically possible.

Additionally, evidence of gender differences in COVID-19 severity have been reported indicating that men are more vulnerable and have a higher risk of infection as well as more severe symptoms than women [3]. It has been hypothesized that the male reproductive system is a potential target of SARS-CoV-2 infection, as the ACE2 receptor, responsible for the virus entry into the host cells, is present in spermatogonia, Sertoli and Leydig cells of the testis, besides its high expression in the lung [4]. Recently, expression of other Coronavirus receptors was demonstrated in spermatogonia stem cell and in prostate gland [5].

Considering that several other viruses could impair testicular function and, most importantly, some of them can be found in semen [6] (for instance hepatitis viruses B and C (HBV and HCV) and the human immunodeficiency virus (HIV)) the possibility that also SARS-CoV-2 can be present in semen cannot be denied “a priori”. We recently assess the association between gonadal function and SARS-CoV-2 clinical outcomes in a cohort of patients admitted in the respiratory intensive care unit, and demonstrated that lower baseline levels of total testosterone and calculated free testosterone levels predicted poor prognosis and mortality while being associated to the onset of hypogonadism with primary testicular impairment [7].

To date, there are no reliable data regarding seminal contamination and transmission of SARS-CoV-2 virus. The large majority of the studies did not report the presence of viral RNA in semen of patients recovered or recovering from COVID-19 [8–14]. However, in few cases of men infected or recovering from SARS-CoV-2, the virus genome was detected in seminal fluid [15–17]. Although according to a recent systematic review [18], the presence of the virus in semen is a rare event, the potential risk of sexual transmission and semen contamination of SARS-CoV-2 remains an open question. Therefore, the risk of handling and managing male gametes during COVID-19 pandemic for cryopreservation and use in Assisted Reproduction Technology (ART) should be considered. Indeed, the use of gametes of subjects positive for SARS-CoV-2 could represent a critical point for the safety and the possible reproductive consequences for couples and personnel involved in ART procedures [19].

Currently, there are no global guidelines for the management of male and female gametes and embryos during ART programs or cryopreservation procedures. However, the American Society for Reproductive Medicine (ASRM), the Society for Assisted Reproductive Technology (SART) and the European Society of Human Reproduction and Embryology (ESHRE) recommended caution to couples planning natural pregnancy or ART [20]. In 2005, the European Union issued mandatory guidelines for the screening of HBV, HCV and HIV viruses in all the patients before undergoing ART or cryopreservation. These viruses (and others) remain viable at temperatures as low as those of liquid nitrogen storage, and the fact that also SARS-CoV-2 could have the same behavior cannot be excluded. Therefore, biobanks dealing with cryopreservation and handling biological samples should apply careful and preventive measures to control and contain also the SARS-CoV-2 infection. However, at present, there is considerable confusion on which precautions to take.

We report here, the results of a survey administered to European semen banks belonging to andrology centers accredited by the European Academy of Andrology (EAA) and by the Italian Society of Andrology and Sexual Medicine (SIAMS) aimed at collecting data on precautions and safety procedures undertaken during the pandemic to minimize the risk of possible semen contamination by SARS-CoV-2.

In addition, we report the experience of Regional Reference Center—Seminal Fluid Cryopreservation—Andrology Laboratory of the Careggi University Hospital of Florence in the period from May 2020 to January 2021, which among all the others was the only one searching SARS-CoV-2 mRNA in semen samples.

Materials and methods

Setting and study participants

To have the widest possible spectrum of participation, we asked European Academy of Andrology (EAA) and the Semen Cryopreservation Committee of Italian Society of Andrology and Sexual Medicine (SIAMS) to send a survey to the accredited centers of their societies including semen banks. The survey focused on the measures adopted during pandemic period for patients undergoing semen cryopreservation. The questionnaire (Table 1) was mailed to the Directors of n = 22 (13 European and 9 Italian) centers and included questions with fixed response options (YES or NO), plus some clarifications in case of affirmative answers.

Table 1.

Questions included in the survey administered to Italian and European semen banks aimed to understand precautions taken during the COVID-19 pandemic to prevent possible semen contamination by SARS-CoV-2

Name of the semen cryopreservation center
Country
Questions
1. In your center, do you administer an anamnestic questionnaire regarding risk of exposition to SARS-CoV-2, previous fever and other symptoms related to COVID-19, to patients undergoing semen cryopreservation?	□ Yes □ No
2. In your center, do you request a NPS to patients before semen cryopreservation? If YES, indicate the validity (i.e., 24, 48, 72 h)	□ Yes □ No
3. In your center, do you request the search of SARS-CoV-2 RNA in semen samples before cryopreservation?	□ Yes □ No
4. In your center, do you use a separate liquid nitrogen tank during pandemic period?	□ Yes □ No
5. In your center, do you use a separate liquid nitrogen tank for NPS positive patients? (in case of answer YES to question 2)	□ Yes □ No
6. In your center, do you use a quarantine liquid nitrogen tank to wait for the report of the NPS? (in case of late report)	□ Yes □ No

Experience of the Regional Reference Center—Seminal Fluid Cryopreservation—Andrology Laboratory of the Careggi University Hospital of Florence

According to the protocol established by the Careggi University Hospital Risk Management Unit, during the pandemic period, patients undergoing semen cryopreservation must exhibit the results of a nasopharyngeal swab (NPS) for SARS-CoV-2 (performed no longer than 72 h prior to semen collection) and must give the consent to use an aliquot of semen sample to search SARS-CoV-2 RNA by RT-PCR.

Semen collection

Semen samples were obtained by masturbation and collected in sterile containers. After liquefaction of the sample and measurement of the volume, an aliquot of the sample (230 µL) was used for the evaluation of the presence of the SARS-CoV-2 virus by RT-PCR and the remained semen volume was used for semen analysis and subsequent cryopreservation according to routine procedure.

Detection of SARS-CoV-2 in semen samples

All the samples were processed on the same day of collection at the center of Microbiology and Virology Unit of the Careggi University Hospital of Florence. Detection of SARS-CoV-2 was performed according to the method previously published [17]. Briefly, sample nucleic acids were extracted with the Microlab Nimbus IVD system (Seegene Inc, Seoul, South Korea) using the Starmag Universal Cartridge kit and amplified with the multiplex RT-PCR Allplex ™ SARS-CoV-2 assay (Seegene Inc), taking as target genes RdrP, E and N, according to the manufacturer’s instructions. The amplification reaction was carried out for a total of 45 cycles and the presence of specific amplification products of the target genes was evaluated using the Ct value through Seegene Viewer analysis software. An exogenous gene target was included prior to nucleic acids extraction to each sample, as required by the manufacturer, and used as internal control to monitor the process of nucleic acid extraction and to exclude the presence of any possible RT-PCR inhibitors.

Data management and analysis

Data of each center were recorded in a database and different percentages related to each answer were calculated. In addition, data regarding the search of SARS-CoV-2 mRNA in semen of subjects undergoing cryopreservation at the Regional Reference Center—Seminal Fluid Cryopreservation—Andrology Laboratory of the Careggi University Hospital of Florence were recorded in a database and the relative percentages calculated.

Results

Answers to survey

All contacted centers performing semen cryopreservation returned completed survey. Types of institutes were 1 private clinic, 17 university hospitals, 4 public hospitals (for details see Table 2).

Table 2.

List of centers participating to the survey

Participating center	Country	Director	Scientific society
Brussels, Center for Reproductive Medicine	Belgium	Prof. Herman Tournaye	EAA
Copenhagen, Dept of Growth and Reproduction	Denmark	Dr. Niels Jørgensen	EAA
Florence, Regional Reference Center—Seminal Fluid Cryopreservation—Andrology Laboratory of the Careggi University Hospital of Florence	Italy	Prof. Linda Vignozzi	EAA, SIAMS
Ghent, Dept’s of Endocrinology, Reproductive Medicine and Urology	Belgium	Dr. Guy T'Sjoen	EAA
Halle-Saale, Center for Reproductive Medicine and Andrology	Germany	Prof. Hermann M. Behre	EAA
L'Aquila, Andrology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila	Italy	Prof. Felice Francavilla	SIAMS
Latina, Andrology and Pathophysiology of Reproduction Unit, Santa Maria Goretti Hospital	Italy	Dr. Pietro Salacone	SIAMS
Leuven, Dept of Endocrinology/Andrology	Belgium	Prof. Dirk Vanderschueren	EAA
Malmo, Reproductive Medicine Center	Sweden	Prof. Aleksander Giwercman	EAA
Milan, Assisted Reproduction Techniques Unit, Ospedale Santi Paolo e Carlo	Italy	Dr. Patrizia Sulpizio	SIAMS
Milan, Infertility Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico	Italy	Prof. Edgardo Somigliana	SIAMS
Moscow, N. A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology	Russia	Prof. Oleg Apolikhin	EAA
Münster, Center of Reproductive Medicine and Andrology	Germany	Prof. Sabine Kliesch	EAA
Padua, Regional Reference Center—Seminal Fluid Cryopreservation—Andrology and Reproductive Medicine	Italy	Prof. Carlo Foresta	SIAMS
Riga, Clinic IVF-Riga	Latvia	Dr. Juris Erenpreiss	EAA
Rome, Laboratory of Seminology-Sperm Bank “Loredana Gandini”, Department of Experimental Medicine, “Sapienza” University of Rome	Italy	Prof. Francesco Lombardo	EAA, SIAMS
Rotterdam, Erasmus Medical Centre	Netherlands	Dr. Gert Dohle	EAA
Siena, Centre for Diagnosis and Treatment of Couple Sterility, Siena University Hospital	Italy	Prof. Vincenzo De Leo	SIAMS
Stockholm, ANOVA—Karolinska University Hospital and Karolinska Institutet	Sweden	Prof. Mats Holmberg and Lars Björndahl	EAA
Thessaloniki, Aristotle University of Thessaloniki	Greece	Prof. Dimitrios Goulis	EAA
Turin, Unit of Andrology, Seminology and Cryopreservation, G.I.D.; Department of Medical Sciences, University of Turin	Italy	Dr. Giovanna Motta	SIAMS
Zagreb, School of Medicine, University of Zagreb	Croatia	Prof. Davor Jezek	EAA

Name, country, director and scientific society of each center are reported

Among the Italian centers (Fig. 1A), 6/9 (66.7%) administer an anamnestic questionnaire on COVID-19 to patients, 3/9 (33.3%) ask for NPS before semen cryopreservation within the 72 h before the procedure. Only the center of Careggi University Hospital (11.1%) performed the search for viral RNA in semen before storing the sample. 3/9 (33.3%) centers store the sample in a quarantine tank in the absence of NPS response and, only two centers, adopt a dedicated tank in case of SARS-CoV-2 positive subjects (22.2%).

Fig. 1.

Stacked bar chart representing the percentages of Italian (panel A, n = 9), European (panel B, n = 13) and all (panel C, n = 22) centers answered Yes or No to questions of survey

Among European centers (Fig. 1B), 11/13 (84.6%) screen patients by administering an anamnestic questionnaire on COVID-19, 7/13 (53.8%) asked NPS results before semen cryopreservation (2 of them within 72 h, 2 within 48 h and 1 within 24 h before the cryopreservation procedure; 2 centers did not indicate the timing of NPS respect to cryopreservation procedure). No center performs the search of viral mRNA in semen before storing the sample. Regarding the use of separate tanks, only 4/13 (30.8%) centers store the sample in a quarantine tank in case of urgent cryopreservation and in the absence of NPS response. Moreover, in case of positive NPS, only 2/13 (15.4%) centers employ a separate tank and only one center uses a separate tank for all semen samples stored during the pandemic period.

All centers accepted to cryopreserve semen samples of patients with a positive NPS (hospitalized or not) when the cryopreservation cannot be delayed for health problems (i.e., oncological patients with the urgency to start the therapies).

Noteworthy, also within European centers of the same country, different protocols are used. In particular, of the two Belgian centers only one requests NPS before cryopreservation; of the two German centers, only one foresees both NPS before cryopreservation and the use of a quarantine tank and, finally, only one of the two Swedish centers administers the anamnestic questionnaire, while the other does not foresee any particular procedure.

The answers of all centers (Italian and European) together are reported in Fig. 1C.

Detection of SARS-CoV-2 in semen samples from subjects who have undergone semen cryopreservation in the Regional Reference Center—Seminal Fluid Cryopreservation—Andrology Laboratory of the Careggi University Hospital of Florence

The presence of the SARS-CoV-2 viral genome was investigated by RT-PCR in the seminal matrices of 111 subjects who performed the collection of semen for cryopreservation in our Lab in the period May 2020–January 2021 independently of the NPS results. Figure 2 shows the pie chart representing the percentage of oncological (81/111 subjects, 73.0%) and non-oncological subjects (30/111 subjects, 27.0%), (panel A), who underwent both a NPS (panel B) and a search for the viral RNA in the seminal matrix (panel C). Only two subjects tested positive for NPS (1.8%, panel B), but in neither of them the viral RNA was detected in the matrix (panel C).

Fig. 2.

Pie charts showing the percentages of oncological and non-oncological patients (panel A), the percentages of patients resulted positive or negative to NPS (panel B) and the percentages of patients resulted positive or negative to search of SARS-CoV-2 mRNA in seminal matrix (panel C) related to 111 men attending to the Regional Reference Center—Seminal Fluid Cryopreservation—Andrology Laboratory of the Careggi University Hospital of Florence for semen cryopreservation

Discussion

Due to its rapid global spread, high transmissibility and high frequency of complications, since the end of 2019, the world has been fighting to keep the SARS-CoV-2 pandemic under control. Infection occurs primarily through respiratory droplets, however, other routes of transmission cannot be excluded, increasing the possibility of the impact of SARS-CoV-2 on multiple organs. It has been hypothesized that the male reproductive system is a potential target for SARS-CoV-2 infection [4]. In this scenario, there are rising concerns on how SARS-CoV-2 infection could affect male fertility as well as possibilities of seminal contamination and transmission.

In many countries, following recommendations of some international scientific societies, whenever possible, fertility treatments were postponed, however, semen cryopreservation, in case of oncological patients undergoing gonadotoxic therapies, could not be brought to a standstill. Therefore, there was an urgent need to understand which are the risks associated with the collection and the processing of human male gametes during COVID-19 pandemic, and, in particular, the hazards related to the banking of these samples, which theoretically could be infected with SARS-CoV-2.

Especially at the beginning, very little knowledge was available about this new virus, hence, public and private laboratories tried to activate measures and protocols to ensure the safety of both samples they managed and stored, and the staff who handled them. However, the management of sperm cells raised several concerns on what were the correct measures to adopt.

To our knowledge, this is the first survey investigating the preventive measures and procedures applied during COVID-19 pandemic on semen cryopreservation. To have the most possible complete picture both at national and European level, we asked two important andrology societies to stimulate semen cryopreservation centers to fulfill the survey.

As reported in the results, no particularly drastic measures were taken by the majority of centers to prevent the risk of contamination or transmission of SARS-CoV-2 infection. Indeed, the most common strategy adopted by the centers (77.3%) was the administration of a questionnaire to men before cryopreservation to evaluate possible contacts with infected people or the presence of symptoms attributable to COVID-19. Whether this strategy can be sufficient to exclude infection is questionable, as asymptomatic subjects have been described [21]. Most of the centers do not request NPS before cryopreservation (from 24 to 72 h before sample collection and freezing). Moreover, in case of the absence of NPS response on time, only few centers use a quarantine tank. Of note, in the event of a NPS positive patient, only 4/22 laboratories store the sample in a dedicated tank. The use of separate tanks for subjects with serum virus positivity is indicated in the last two editions of WHO manual [22, 23], but different countries have different rules regarding this point. Italian legislation for gamete cryopreservation has established that it is necessary to have dedicated cryogenic containers for each of the different screened pathologies [24]. However, until now, no cross-contamination among cryopreserved semen samples were recorded also thank to the employment of highly secure devices and segregated cryovessels [25].

Although all centers participating to the survey performed semen cryopreservation in case of NPS positive patients that cannot delay because of initiation of lifesaving therapies, it is necessary that semen collection is performed outside of the laboratory (at home or in the hospital in case of hospitalized patients). The bank should foresee an accurate sanitization of all the devices and adopt specific security measures and protocols to ensure the safety of the operators employed in the center as well as of the other samples.

According to data available in literature, the risk of sexual transmission of SARS-CoV-2 from semen due to presence of virus or contamination is low [18], although larger cohort of subjects will be required to have a clear picture on this risk.

The experience of the Regional Reference Center—Seminal Fluid Cryopreservation—Andrology Laboratory of the Careggi University Hospital of Florence, being the only center among those participating to the survey that searched for SARS-CoV-2 RNA in the seminal matrix, strengthened such a fact. Indeed, the viral genome was not detected in the semen of any of the 111 patients undergoing cryopreservation, including two men who resulted positive to NPS in agreement with the majority of the previous studies [8–14]. In addition, in a recent observational cohort trial, no detectable viral RNA was found in different fluids of reproductive tracts, including semen, of subjects undergoing ART, of which few with a positive NPS [26], confirming that the risk of occurrence of the virus in such fluids is minimal. However, considering that currently there are no validated methods for detection of SARS-CoV-2 RNA in semen, the use of a separate tank in case of semen sample of NPS positive patients could represent a further security measure.

In conclusion, this survey revealed that semen banks operating in Europe use variable measures to handle and manage semen samples for cryopreservation during COVID-19 pandemic period. In particular, most centers do not even require an NPS of the patient before the procedure. Although current evidence indicates low risk for sexual transmission of the virus, knowing the results of an NPS is advised in our opinion because it could be important in couple counseling when using the sample in an ART center. In addition, the personnel operating in the bank/ART center is warned of managing possible infected semen. Knowledge about this Coronavirus is still limited but in continuous evolution; therefore, it is advisable to behave with the utmost caution and use safe devices for sample handling and storage.

Declarations

Conflict of interest

On behalf of all the authors, the corresponding author states that there is no conflict of interest. L. Vignozzi is a member of the Editorial Board of the journal.

Ethical approval

The data reported in this study derive from a questionnaire administered to European semen banks. The questions in the survey do not concern human biological samples but only the cryopreservation procedures adopted during COVID-19 pandemic. For these reasons, the ethics approval is not required. However, semen cryopreservation procedures performed in all centers were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual patients undergoing semen cryopreservation.